ArticleJournal of managed care & specialty pharmacy2023

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.

Larysa Sanchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.